Get started
Author

David Gomez Jimenez

Observed names: D. Gomez Jimenez, David G. Jimenez, David Gomez-Jimenez
ORCID: 0000-0002-9375-5263
Observed ORCID: 0000-0002-9375-5263
OpenAlex ID: A5062186545
Restoring tumor immunogenicity with dendritic cell reprogramming
2023 · Olga Zimmermannova, Alexandra G. Ferreira, et al. · Science Immunology · 97
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
2022 · Karin Hägerbrand, Laura Varas, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
2025 · Jean-Luc Van Laethem, Karen Geboes, et al. · Cell Reports Medicine · 11
Tonsillar Cancer with High CD8+ T-Cell Infiltration Features Increased Levels of Dendritic Cells and Transcriptional Regulation Associated with an Inflamed Tumor Microenvironment
2021 · David Gomez Jimenez, Aastha Sobti, et al. · Cancers · 10
PDF
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
2023 · Hampus Andersson, Aastha Sobti, et al. · Cells · 8
PDF
Single-cell analysis of myeloid cells in HPV+ tonsillar cancer
2023 · David Gomez Jimenez, Can Altunbulakli, et al. · Frontiers in Immunology · 8
Targeted spatial proteomic analysis of CD8+ T- and myeloid cells in tonsillar cancer
2023 · Can Altunbulakli, David G. Jimenez, et al. · Frontiers in Oncology · 6
PDF
Pattern recognition receptor expression and maturation profile of dendritic cell subtypes in human tonsils and lymph nodes
2021 · David Askmyr, Milad Abolhalaj, et al. · Human Immunology · 5
PDF
OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
2024 · Jean-Luc Van Laethem, Ivan Borbath, et al. · Journal of Clinical Oncology · 2
Abstract 2376: Mitazalimab, a potent CD40 agonist in combination with FOLFIRINOX demonstrates changes consistent with increased immune activation in TME and peripheral blood in a preclinical pancreatic cancer tumor model
2024 · Karin Enell Smith, David Gomez Jimenez, et al. · Cancer Research · 2
Abstract C038: Interim pharmacodynamic analyses of mitazalimab in combination with FOLFIRINOX in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) identify CD4 effector T cells as a correlate of treatment outcomes
2024 · Max M. Wattenberg, Karin Enell Smith, et al. · Cancer Research · 2
CD4 effector T cell expansion to identify objective responses to the CD40 agonist mitazalimab in combination with modified FOLFIRINOX (mFFX) as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC) in the OPTIMIZE-1 study.
2024 · Max Miller Wattenberg, Karin Enell Smith, et al. · Journal of Clinical Oncology · 1
PDF
837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
2023 · Ida Uddbäck, Sara Fritzell, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract A40: Restoring tumor immunogenicity with dendritic cell reprogramming
2022 · Alexandra G. Ferreira, Olga Zimmermannova, et al. · Cancer Immunology Research · 1
Reprogramming Human Cancer Cells into Antigen Presentation
2021 · Olga Zimmermannova, Ilia Kurochkin, et al. · Blood · 1
Subpopulations of Organoid-Forming Cells Have Different Motility
2020 · David Gomez Jimenez, Sofia Carreira Santos, et al. · Applied Sciences · 1
PDF
Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer.
2025 · Philippe Alexandre Cassier, Jean-Luc Van Laethem, et al. · Journal of Clinical Oncology
762 ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces myeloid and T-cell dependent anti-tumor activity and synergizes with PD-1 inhibition
2024 · Ida Uddbäck, Hampus Andersson, et al. · Journal for ImmunoTherapy of Cancer
592 CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): updated efficacy and correlative biomarkers from the OPTIMIZE-1 trial
2024 · Karen P Geboes, Gregory Beatty, et al. · Journal for ImmunoTherapy of Cancer
PDF
280MO CD40 agonist mitazalimab combined with mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Primary analysis of the OPTIMIZE-1 phase Ib/II study
2024 · T. Macarulla Mercade, I. Borbath, et al. · Annals of Oncology
PDF
Abstract 5309: ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, induces tumor localized immune cell activation in preclinical in vivo tumor model
2024 · Hampus Andersson, Ida Uddbäck, et al. · Cancer Research
Abstract 2939: ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo
2023 · Karin Hägerbrand, Anette Sundstedt, et al. · Cancer Research
840 Presence and distribution of immunosuppressive peptide P3028 in relation to immune phenotype of tonsillar cancer
2020 · Sabine Swoboda, Rebecca Rosberg, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 23
Citation count: 190
H-index: 6
I10-index: 4
Year
Topic
Type